Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico
Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico
研究概览
详细说明
A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) will be selected from the total population that participated in the Encuesta Nacional de Salud y Nutrición (ENSANUT) 2012 in Mexico.
Data (through structured questionnaires and interviews) and stored serum samples of the selected subjects obtained from the ENSANUT 2012 will be used in this study. A subset database will be designed by the National Institute of Public Health (NIPH) for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in this database.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Morelos
-
Cuernavaca、Morelos、墨西哥
- GSK Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Written informed consent for the ENSANUT 2012 was obtained according to local regulations from the subject/ from the parent(s)/ legally acceptable representative (LAR) of the subject.
- A male or female between and including 10 and 25 years of age, who previously participated in the ENSANUT 2012 in Mexico.
Exclusion Criteria:
- Information required for the study is not available or incomplete.
- Inadequate or insufficient serum sample to perform the laboratory tests for this study.
- Serum sample is wrongly identified.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Study Group
A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) that participated in the ENSANUT 2012 in Mexico.
|
Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012.
A subset database will be designed by the NIPH for the purpose of this study.
Extracted data and laboratory results of the selected subjects will be captured in the study database.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HAV
大体时间:During the study (approximately 12 months)
|
During the study (approximately 12 months)
|
|
Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HBV (Hepatitis B core antibody [anti-HBc], Hepatitis B surface antigen [HBsAg]) and Hepatitis B surface antibody (anti-HBs)
大体时间:During the study (approximately 12 months)
|
During the study (approximately 12 months)
|
|
Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for Pertussis antibodies
大体时间:During the study (approximately 12 months)
|
During the study (approximately 12 months)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Assesment of the difference in HAV, HBV and B. pertussis seropositivity rates among - Socioeconomic strata, - Regions, - Age groups, - Genders, - Risk groups, - Vaccination status for B. pertussis (if available)
大体时间:During the study (approximately 12 months)
|
During the study (approximately 12 months)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.